Literature DB >> 18787832

Enhanced induction of apoptosis in a radio-resistant bladder tumor cell line by combined treatments with X-rays and wortmannin.

Trinidad Ortiz1, Miguel Angel Burguillos, Guillermo López-Lluch, Plácido Navas, Miguel Herrador, Isabel González, Joaquín Piñero.   

Abstract

The radiosensitizing effect of wortmannin (WM) treatment during and after irradiation was studied in radioresistant bladder tumor cell lines with normal (MGH-U1 cells) or defective p53 activity (RT112 cells). WM modulated G(2)/M cell cycle arrest induced by higher X-ray doses (10 Gy) in both cell lines, although the alteration was significant only in RT112 cells. The observation suggests that WM activity is independent of p53. Constitutive expression of DNA-PKcs was found to be higher in RT112 cells than in MGH-U1. Treatment with WM enhanced radiation-induced apoptosis significantly in RT112 cells while it had no effect on MGH-U1 cells. Although a variety of PI3-kinases and PI3-K like kinases (including ATM) could be inhibited by WM, our observation of increased early lethality by WM treatment in RT112 is in agreement with previous results. They suggest that the WM-dependent radiosensitization of RT112 is a direct consequence of the inhibition of DNA-PK, resulting in the inhibition of DSB repair in the fast component. This early effect in the p53 deficient cell line could also indicate that processes other than apoptosis may contribute to the increased radiosensitization. In our opinion, the expression level of DNA-PKcs in human tumor cells may be a good predictor for the success of DNA-PKcs inhibitors when used as radiosensitizers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18787832     DOI: 10.1007/s00411-008-0188-6

Source DB:  PubMed          Journal:  Radiat Environ Biophys        ISSN: 0301-634X            Impact factor:   1.925


  36 in total

1.  Wortmannin sensitizes human glioblastoma cell lines carrying mutant and wild type TP53 gene to radiation.

Authors:  N Kubota; S Okada; T Inada; K Ohnishi; T Ohnishi
Journal:  Cancer Lett       Date:  2000-12-20       Impact factor: 8.679

2.  Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction.

Authors:  M P Wymann; G Bulgarelli-Leva; M J Zvelebil; L Pirola; B Vanhaesebroeck; M D Waterfield; G Panayotou
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

3.  Cell cycles in two cell lines of human bladder carcinoma.

Authors:  T Kato; R J Irwin; G R Prout
Journal:  Tohoku J Exp Med       Date:  1977-02       Impact factor: 1.848

4.  Increased sensitivity to chromatid aberration induction by bleomycin and neocarzinostatin results from alterations in a DNA damage response pathway.

Authors:  T Allio; R J Preston
Journal:  Mutat Res       Date:  2000-09-20       Impact factor: 2.433

5.  DNA-dependent protein kinase acts upstream of p53 in response to DNA damage.

Authors:  R A Woo; K G McLure; S P Lees-Miller; D E Rancourt; P W Lee
Journal:  Nature       Date:  1998-08-13       Impact factor: 49.962

6.  Pharmacological inhibition of DNA repair enzymes differentially modulates telomerase activity and apoptosis in two human leukaemia cell lines.

Authors:  D Dubner; M del Rosario Pérez; S Michelin; M Bourguignon; P Moreau; E D Carosella; P Gisone
Journal:  Int J Radiat Biol       Date:  2004-08       Impact factor: 2.694

7.  p53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase.

Authors:  André Fedier; Ahmed Moawad; Urs Haller; Daniel Fink
Journal:  Int J Oncol       Date:  2003-11       Impact factor: 5.650

Review 8.  The radioresponsiveness of human tumours and the initial slope of the cell survival curve.

Authors:  J Deacon; M J Peckham; G G Steel
Journal:  Radiother Oncol       Date:  1984-12       Impact factor: 6.280

9.  Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

Authors:  Yan Zhao; Huw D Thomas; Michael A Batey; Ian G Cowell; Caroline J Richardson; Roger J Griffin; A Hilary Calvert; David R Newell; Graeme C M Smith; Nicola J Curtin
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

10.  Relationship between p53 status and radiosensitivity in human tumour cell lines.

Authors:  E Siles; M Villalobos; M T Valenzuela; M I Núñez; A Gordon; T J McMillan; V Pedraza; J M Ruiz de Almodóvar
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

View more
  5 in total

1.  Cisplatin associated with LY294002 increases cytotoxicity and induces changes in transcript profiles of glioblastoma cells.

Authors:  P O Carminati; F S Donaires; M M Marques; E A Donadi; G A S Passos; E T Sakamoto-Hojo
Journal:  Mol Biol Rep       Date:  2013-11-12       Impact factor: 2.316

2.  TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma.

Authors:  Dana L Casey; Kenneth L Pitter; Leonard H Wexler; Emily K Slotkin; Gaorav P Gupta; Suzanne L Wolden
Journal:  Br J Cancer       Date:  2021-05-20       Impact factor: 7.640

3.  DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.

Authors:  Rui-Xue Huang; Ping-Kun Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-05-01

4.  The synergistic effects of traditional Chinese herbs and radiotherapy for cancer treatment.

Authors:  Lili Jia; Shumei Ma; Xue Hou; Xin Wang; Abu Baker Layth Qased; Xuefei Sun; Nan Liang; Huicheng Li; Heqing Yi; Dejuan Kong; Xiaodong Liu; Feiyue Fan
Journal:  Oncol Lett       Date:  2013-03-12       Impact factor: 2.967

5.  Theasaponin E1 Inhibits Platinum-Resistant Ovarian Cancer Cells through Activating Apoptosis and Suppressing Angiogenesis.

Authors:  Bo Li; Tuantuan Tong; Ning Ren; Gary O Rankin; Yon Rojanasakul; Youying Tu; Yi Charlie Chen
Journal:  Molecules       Date:  2021-03-17       Impact factor: 4.927

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.